TLSA
Tiziana Life Sciences Ltd. Common Shares
Latest price
As of Oct 27, 2026, 6:54 PM EDT · Market data by Massive
Market cap
$112.3M
Volume
190.5K
Previous close
$0.8823
Day range
$0.8720 – $0.9429
Listed
Nov 20, 2018
Coverage
3 articles
Price performance
Recent trading
Newsroom
Latest TLSA coverage
AccuStem Sciences, Inc. Extends and Broadens Partnership with Instituto Europeo di Oncologia (IEO) Enabling its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast Cancer
AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, signs further agreement with the IEO, one of the most renowned comprehensive cancer centers in Europe.
Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference in Sweden
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Dr. Howard Weiner will present positive data from a study of intranasal anti-CD3 monoclonal antibody in an animal model of Alzheimer’s disease on April 1, 2023 at the AD/PD 2023 Internat
Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it has received feedback based on the U.S. Food and Drug Administration (FDA) Type C meeting minutes related to the Phase 2 clinical trial of intranasal foralumab in patients with non-active